English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/212335
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:

Title

Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping

AuthorsZugazagoitia, Jon; Ramos, Inmaculada ; Trigo, José Manuel; Palka, M.; Gómez-Rueda, Ana; Jantus-Lewintre, Eloisa; Camps, Carlos; Isla, María Dolores; Iranzo, P.; Ponce-Aix, Santiago; García-Campelo, R.; Provencio, Mariano; Franco, F.; Bernabé Caro, Reyes; Juan-Vidal, Óscar; Felip, Enriqueta; Castro, Javier de; Sánchez-Torres, J. M.; Faul, Iris; Lanman, R. B.; Garrido, Pilar; Paz-Ares, Luis
KeywordsLung adenocarcinoma
Insufficient tissue
ctDNA
Digital next-generation sequencing
Actionable genomic alterations
Co-occurring genomic alterations
Issue Date2019
PublisherElsevier
CitationAnnals of Oncology 30(2): 290-296 (2019)
Abstract[Background] Approximately 30% of tumor biopsies from patients with advanced-stage lung adenocarcinomas yield insufficient tissue for successful molecular subtyping. We have analyzed the clinical utility of next-generation sequencing (NGS) of cell-free circulating tumor DNA (ctDNA) in patients with inadequate tumor samples for tissue genotyping. [Patients and methods] We conducted the study in a multi-institutional prospective cohort of clinically unselected patients with advanced-stage lung adenocarcinomas with insufficient tissue for EGFR, ALK or ROS1 genotyping across 12 Spanish institutions (n = 93). ctDNA NGS was carried out by Guardant Health (Guardant360, Redwood City, CA), using a hybrid-capture-based 73-gene panel. Variants were deemed actionable if they were part of the OncoKB precision oncology knowledge database and classified in four levels of actionability based on their clinical or preclinical evidence for drug response. [Results] Eighty-three out of 93 patients (89%) had detectable levels of ctDNA. Potentially actionable level 1–4 genomic alterations were detected in 53 cases (57%), of which 13 (14%) had level 1–2A alterations (Food and Drug Administration-approved and standard-care biomarkers according to lung cancer guidelines). Frequencies of each genomic alteration in ctDNA were consistent with those observed in unselected pulmonary adenocarcinomas. The majority of the patients (62%), particularly those with actionable alterations (87%), had more than one pathogenic variant in ctDNA. The median turnaround time to genomic results was 13 days. Twelve patients (13%) received genotype-matched therapies based on ctDNA results, deriving the expected clinical benefit. Patients with co-occurring pathogenic alterations had a significantly shorter median overall survival as compared with patients without co-occurring pathogenic alteration (multivariate hazard ratio = 5.35, P = 0.01). [Conclusion] Digital NGS of ctDNA in lung cancers with insufficient tumor samples for tissue sequencing detects actionable variants that frequently co-occur with other potentially clinically relevant genomic alterations, allowing timely initiation of genotype-matched therapies.
Publisher version (URL)https://doi.org/10.1093/annonc/mdy512
URIhttp://hdl.handle.net/10261/212335
Identifiersdoi: 10.1093/annonc/mdy512
e-issn: 1569-8041
issn: 0923-7534
Appears in Collections:(IBIS) Artículos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdf15,38 kBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.